Is VALIANTLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VALIANTLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VALIANTLAB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VALIANTLAB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VALIANTLAB?
Key metric: As VALIANTLAB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for VALIANTLAB. This is calculated by dividing VALIANTLAB's market cap by their current
revenue.
What is VALIANTLAB's PS Ratio?
PS Ratio
4.3x
Sales
₹1.11b
Market Cap
₹4.82b
VALIANTLAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
4.3x
Enterprise Value/EBITDA
-23.7x
PEG Ratio
n/a
Price to Sales Ratio vs Peers
How does VALIANTLAB's PS Ratio compare to its peers?
The above table shows the PS ratio for VALIANTLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Price-To-Sales vs Industry: VALIANTLAB is expensive based on its Price-To-Sales Ratio (4.4x) compared to the Indian Pharmaceuticals industry average (3.1x).
Price to Sales Ratio vs Fair Ratio
What is VALIANTLAB's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
VALIANTLAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
4.3x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate VALIANTLAB's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.